Discovery of an Orally Bioavailable and Selective PKMYT1 Inhibitor, RP-6306.
Sign Up to like & getrecommendations! Published in 2022 at "Journal of medicinal chemistry"
DOI: 10.1021/acs.jmedchem.2c00552
Abstract: PKMYT1 is a regulator of CDK1 phosphorylation and is a compelling therapeutic target for the treatment of certain types of DNA damage response cancers due to its established synthetic lethal relationship with CCNE1 amplification. To… read more here.
Keywords: pkmyt1 inhibitor; pkmyt1; discovery orally; orally bioavailable ... See more keywords
c-Myb-mediated inhibition of miR-601 in facilitating malignance of osteosarcoma via augmentation of PKMYT1
Sign Up to like & getrecommendations! Published in 2022 at "Scientific Reports"
DOI: 10.1038/s41598-022-10684-0
Abstract: The crosstalk between osteosarcoma (OS) development and abnormally expressed microRNA (miR)-601 is not explored explicitly. Here, we identified the downregulated miR-601 in osteosarcoma (OS) through a comprehensive bioinformatics analysis of GEO Datasets. The results indicated… read more here.
Keywords: pkmyt1; mir 601; osteosarcoma; mir ... See more keywords
Demethylase ALKBH5 suppresses invasion of gastric cancer via PKMYT1 m6A modification
Sign Up to like & getrecommendations! Published in 2022 at "Molecular Cancer"
DOI: 10.1186/s12943-022-01522-y
Abstract: Background Gastric cancer (GC) is one of the most pernicious tumors that seriously harm human healthcare. GC metastasis is one of the prime cause of failed cancer treatment, but correlation between N6-methyladenosine (m6A) and GC… read more here.
Keywords: cancer; alkbh5; metastasis; m6a ... See more keywords
Overexpressed PKMYT1 promotes tumor progression and associates with poor survival in esophageal squamous cell carcinoma
Sign Up to like & getrecommendations! Published in 2019 at "Cancer Management and Research"
DOI: 10.2147/cmar.s214243
Abstract: Background Esophageal squamous cell carcinoma (ESCC) is one of the most common malignant tumors worldwide and the 5-year overall survival rate remains poor. Protein kinase, membrane associated tyrosine/threonine (PKMYT1) is overexpressed in several cancers and… read more here.
Keywords: pkmyt1; progression; pkmyt1 escc; esophageal squamous ... See more keywords
High expression of PKMYT1 predicts poor prognosis and aggravates the progression of osteosarcoma via the NF κB pathway in MG63 cells.
Sign Up to like & getrecommendations! Published in 2023 at "Current cancer drug targets"
DOI: 10.2174/1568009623666230206154944
Abstract: BACKGROUND Protein kinase, membrane associated tyrosine/threonine 1 (PKMYT1) contributes to the proliferative, migratory, invasive and colony forming capabilities of oncocytes. Dysregulated expression of PKMYT1 is associated with numerous malignancies. However, at present, the functional role… read more here.
Keywords: osteosarcoma; pkmyt1; expression; mg63 cells ... See more keywords
Protein kinase, membrane‑associated tyrosine/threonine 1 is associated with the progression of colorectal cancer.
Sign Up to like & getrecommendations! Published in 2018 at "Oncology reports"
DOI: 10.3892/or.2018.6371
Abstract: The protein kinase, membrane‑associated tyrosine/threonine 1 (PKMYT1) is known to inhibit precocious entry into mitosis by phosphorylating CDK1 at Thr14 and Tyr15 residues. However, the functional importance of PKMYT1 in colorectal cancer (CRC) remains unknown. Thus,… read more here.
Keywords: pkmyt1; associated tyrosine; membrane associated; protein kinase ... See more keywords